Last reviewed · How we verify
Axial Spondyloarthritis
Approved treatments
- tumor necrosis factor inhibitors (TNFi) · Pfizer
- Abrilada · AbbVie
Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors. - Humira · AbbVie
Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors. - TNF Inhibitor · Pfizer
- CYLTEZO · BOEHRINGER INGELHEIM
- Humira · Sohag University
Pipeline
- Tofacitinib 5 MG · Pfizer Inc. — preclinical
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Axial Spondyloarthritis patent landscape — cliff calendar, originator estates, attackable patents
- Axial Spondyloarthritis treatment landscape brief
- Axial Spondyloarthritis treatment updates RSS
Frequently asked questions about Axial Spondyloarthritis
What drugs treat Axial Spondyloarthritis?
Tracked treatments include tumor necrosis factor inhibitors (TNFi), Abrilada, Humira, TNF Inhibitor, CYLTEZO.
What is the treatment for Axial Spondyloarthritis?
Standard treatment for Axial Spondyloarthritis includes tumor necrosis factor inhibitors (TNFi), Abrilada, Humira, TNF Inhibitor, CYLTEZO. See the treatment landscape page for first-line, second-line and salvage options.
What new drugs are in development for Axial Spondyloarthritis?
1 pipeline drugs tracked. Top candidates: Tofacitinib 5 MG.
Related
- Treatment landscape: Axial Spondyloarthritis patent cliff · Axial Spondyloarthritis CI report
- Treatment: tumor necrosis factor inhibitors (TNFi) · Pfizer
- Treatment: Abrilada · AbbVie
- Treatment: Humira · AbbVie
- Treatment: TNF Inhibitor · Pfizer
- Treatment: CYLTEZO · BOEHRINGER INGELHEIM
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing